Enlivex Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ENLV and other ETFs, options, and stocks.About ENLV
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.
CEOOren Hershkovitz
CEOOren Hershkovitz
Employees49
Employees49
HeadquartersNess Ziona, Tel Aviv
HeadquartersNess Ziona, Tel Aviv
Founded2012
Founded2012
Employees49
Employees49
ENLV Key Statistics
Market cap30.49M
Market cap30.49M
Price-Earnings ratio-1.04
Price-Earnings ratio-1.04
Dividend yield—
Dividend yield—
Average volume132.83K
Average volume132.83K
High today$1.66
High today$1.66
Low today$1.52
Low today$1.52
Open price$1.59
Open price$1.59
Volume45.80K
Volume45.80K
52 Week high$4.59
52 Week high$4.59
52 Week low$1.15
52 Week low$1.15
ENLV News
TipRanks 5d
Enlivex Therapeutics: Promising Trial Results for AllocetraEnlivex Therapeutics (ENLV) has released an update. Enlivex Therapeutics, a clinical-stage immunotherapy company, has reported promising results from Phase II...